Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S.

Ann Oncol. 2013 May;24(5):1253-61. doi: 10.1093/annonc/mds622. Epub 2012 Dec 11.

PMID:
23233651
2.

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04. Review.

3.

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.

Gastric Cancer. 2016 Jan;19(1):183-91. doi: 10.1007/s10120-015-0471-6. Epub 2015 Feb 15.

PMID:
25682441
4.

Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A.

Hum Pathol. 2014 May;45(5):970-5. doi: 10.1016/j.humpath.2013.12.010. Epub 2014 Jan 8.

PMID:
24656529
5.

[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

Bouché O, Penault-Llorca F.

Bull Cancer. 2010 Dec;97(12):1429-40. doi: 10.1684/bdc.2010.1224. Review. French.

6.

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants.

N Engl J Med. 2006 Jul 6;355(1):11-20.

7.

High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.

Bichev D, Treese C, von Winterfeld M, Breithaupt K, Dogan Y, Schmidt SC, Daum S, Thuss-Patience PC.

Oncology. 2015;89(2):95-102. doi: 10.1159/000376550. Epub 2015 Mar 21.

PMID:
25823985
8.

Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.

Sirohi B, Barreto SG, Singh A, Batra S, Mittra A, Rastogia S, Ramadwar M, Shetty N, Goel M, Shrikhande SV.

J Cancer Res Ther. 2014 Oct-Dec;10(4):866-70. doi: 10.4103/0973-1482.146122.

9.

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF.

Ann Oncol. 2013 Jul;24(7):1754-61. doi: 10.1093/annonc/mdt106. Epub 2013 Mar 22.

10.

Chemotherapy of oesophago-gastric cancer.

Ross PJ, Rao S, Cunningham D.

Pathol Oncol Res. 1998;4(2):87-95. Review.

11.

A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).

Kataoka K, Tokunaga M, Mizusawa J, Machida N, Katayama H, Shitara K, Tomita T, Nakamura K, Boku N, Sano T, Terashima M, Sasako M; Stomach Cancer Study Group/Japan Clinical Oncology Group..

Jpn J Clin Oncol. 2015 Nov;45(11):1082-6. doi: 10.1093/jjco/hyv134. Epub 2015 Sep 9.

PMID:
26355164
12.

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

Okines AF, Gonzalez de Castro D, Cunningham D, Chau I, Langley RE, Thompson LC, Stenning SP, Saffery C, Barbachano Y, Coxon F, Middleton G, Ferry D, Crosby T, Madhusudan S, Wadsley J, Waters J, Hall M, Swinson D, Robinson A, Smith D, Reis-Filho JS, Waddell TS, Puckey L, Hulkki Wilson S, Eltahir Z, Band M, Wotherspoon A.

Eur J Cancer. 2013 Jun;49(9):2116-25. doi: 10.1016/j.ejca.2013.02.007. Epub 2013 Mar 5.

PMID:
23481512
13.

Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.

Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, Harrison RA, Mitchell IC.

Clin Oncol (R Coll Radiol). 2000;12(3):182-7.

PMID:
10942336
14.

Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.

Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA.

Eur J Surg Oncol. 2015 Mar;41(3):333-8. doi: 10.1016/j.ejso.2014.11.040. Epub 2014 Nov 26.

PMID:
25498359
15.

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.

De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H.

Br J Cancer. 2015 Nov 3;113(9):1305-12. doi: 10.1038/bjc.2015.342. Epub 2015 Oct 20.

16.

Targeted HER2 treatment in advanced gastric cancer.

Jørgensen JT.

Oncology. 2010;78(1):26-33. doi: 10.1159/000288295. Epub 2010 Feb 25.

PMID:
20185938
17.

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.

Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I.

Br J Cancer. 2009 Jun 2;100(11):1725-30. doi: 10.1038/sj.bjc.6605070. Epub 2009 May 12.

18.

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.

Phillips BE, Tubbs RR, Rice TW, Rybicki LA, Plesec T, Rodriguez CP, Videtic GM, Saxton JP, Ives DI, Adelstein DJ.

Dis Esophagus. 2013 Apr;26(3):299-304. doi: 10.1111/j.1442-2050.2012.01369.x. Epub 2012 Jun 7.

PMID:
22676551
19.

The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.

Chua YJ, Cunningham D.

Ann Surg Oncol. 2007 Oct;14(10):2687-90. Epub 2007 Jul 27. No abstract available.

PMID:
17653804
20.

Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.

Watson S, Validire P, Cervera P, Zorkani N, Scriva A, Lemay F, Tournigand C, Perniceni T, Garcia ML, Bennamoun M, Paye F, Louvet C.

Ann Oncol. 2013 Dec;24(12):3035-9. doi: 10.1093/annonc/mdt393. Epub 2013 Oct 10.

PMID:
24114855

Supplemental Content

Support Center